This protocol covers the evidence-based approach to management following surgical resection in patients with stage IIA cutaneous melanoma — a population with specific guidance regarding adjuvant therapy.
The patient has undergone resection of stage IIA cutaneous melanoma (amelanocytic melanoma, ICD-10 C43.9 / ICD-11 2C30.Z). This post-resection setting carries a well-defined evidence-based recommendation that applies broadly across this stage IIA population.
The protocol provides a strong, consensus-backed recommendation on the role of adjuvant therapy in this resected stage IIA setting — with explicit guidance on when and whether additional treatment is appropriate. The complete structured protocol is available below.
DOI: 10.1200/JCO.23.01136
Adjuvant therapy should not be offered to patients with resected stage IIA melanoma outside of enrollment in a clinical trial (Type: Informal consensus; Evidence quality: Not applicable; Strength of Recommendation: Strong).
View source ↗